Dr. Friedman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
94 Old Short Hills Rd
# Saint
Livingston, NJ 07039Phone+1 973-322-5691Fax+1 973-322-5504
Education & Training
- NYU Grossman School of MedicineFellowship, Pediatric Cardiology, 1980 - 1983
- Jacobi Medical Center/Albert Einstein College of MedicineResidency, Pediatrics, 1977 - 1980
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1977
Certifications & Licensure
- NJ State Medical License 1990 - 2025
- NY State Medical License 1978 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Cardiology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- Westchester Magazine: Top Doctors Castle Connolly, 2010-2013
- New York Magazine: Top Doctors Castle Connolly, 2005-2008
- Join now to see all
Publications & Presentations
PubMed
- 100 citationsProspective Evaluation of Fetuses with Autoimmune Associated Congenital Heart Block Followed in the PR Interval and Dexamethasone Evaluation (PRIDE) StudyDeborah M. Friedman, Mimi Y. Kim, Joshua A. Copel, Carolina Llanos, Claudine Davis
The American Journal of Cardiology. 2009-04-15 - 129 citationsSpectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies:Anca Askanase, Deborah M. Friedman, Joshua A. Copel, M R Dische, Anne M. Dubin
Lupus. 2002-03-01 - 483 citationsAutoimmune-Associated Congenital Heart Block: Demographics, Mortality, Morbidity and Recurrence Rates Obtained From a National Neonatal Lupus Registry ☆Jill P. Buyon, Rudi Hiebert, Joshua A. Copel, Joe Craft, Deborah M. Friedman
Journal of the American College of Cardiology. 1998-06-01
Press Mentions
- Zosano Pharma Corporation (NASDAQ: ZSAN) Soars 171% After Final Milestone Completed in Long-Term Safety Study of Qtrypta, a Acute Treatment for Migraine DiseaseFebruary 21st, 2019
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: